Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.

Slides:



Advertisements
Similar presentations
V Glaucoma Implementing NICE guidance 2009 NICE clinical guideline 85.
Advertisements

Susan Boynton, VP, Global Regulatory Affairs, Shire
Keratoconus Research Innovation at CERA Dr Srujana Sahebjada Research Fellow, Optometrist Ocular Genetics Unit.
Slide 1 of 16 Dose Titration in a Patient with Myelodysplastic Syndromes.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Clinical Guidance and Monitoring for Change Cecilia Fenerty MD FRCOphth.
Cataracts in Paediatric patients
The purpose of this study is to use statistical and classification models to classify, detect and understand progression in visual fields (VFs) We intend.
Rites of Sight Your Second 50 years A Presentation of the American Optometric Association.
Incidence of Blepharitis in Patients Undergoing Phacoemulsification Jodi Luchs, MD Carlos Buznego, MD William Trattler, MD The authors of this poster have.
Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
The Effect of the Restor Multifocal IOL on Frequency Doubling Perimetry Elizabeth Yeu, MD1, Elizabeth Woznak, BS2, Nicole Kesten, BS2, Steven VL Brown,
The Canadian Association of Optometrists
Better Health. No Hassles. A Healthy Eyes Healthy People Presentation Glaucoma… Knowing the Facts Can Save Your Sight.
Glaucoma New Zealand - A Charitable Trust. Glaucoma New Zealand’s objectives are to: Eliminate blindness and visual disability from glaucoma in our community.
Eleni Galani Medical Oncologist
Duchenne Muscular Dystrophy: Cardiac Management. Introduction Aim: early detection and treatment of deterioration in heart muscle function Cardiac disease.
Multiple Choice Questions for discussion
HOME AND AMBULATORY BLOOD PRESSURE MONITORING
The Diabetic Retinopathy Clinical Research Network
Will my Glaucoma patient lose vision ?
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
RANDOMIZED CLINICAL TRIALS IN GLAUCOMA- WHAT DO THEY TELL US? Dr Jyoti Shetty B.W.Lions superspeciality eye hospital.
PERIODIC MEDICAL EXAMINATION BY DR. ANGELA ESOIMEME MBBS, MPH, FWACGP.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?
Macugen (pegaptanib sodium injection) Dermatology and Ophthalmology Advisory Committee Meeting Rockville, Maryland August 27, 2004 Dermatology and Ophthalmology.
Hypertension: Blood Pressure Measurement and the new NICE guideline Prof Richard McManus BHS Annual Meeting Cambridge 2011 NICE clinical guideline 127.
EVIDENCE ABOUT DIAGNOSTIC TESTS Min H. Huang, PT, PhD, NCS.
Cataract Surgery After Trabeculectomy: The Effect on Trabeculectomy Function Husain R, Liang S, Foster PJ. Cataract surgery after trabeculectomy: the effect.
Effect of Corneal Thickness on Selective Laser Trabeculoplasty to Decrease Intraocular Pressure as Primary or Secondary Treatment of Glaucoma ASCRS 2010.
Safety and efficacy of bromfenac ophthalmic solution 0.09% (Xibrom™) compared to prednisolone acetate 1% for treatment of ocular inflammation following.
How Do I Know My Glaucoma Treatment is Working? Dr Catherine Green Head: Glaucoma Unit RVEEH.
RETINOPATHY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Effect of Race on Selective Laser Trabeculoplasty  1st author has no financial interest in the subject matter of this poster.  2nd and 3rd co-authors.
Introduction  Selective Laser Trabeculoplasty (SLT) uses a Q-Switched frequency- doubled (532 nm), low energy Nd:YAG laser, which targets melanocytes.
PHACO-TRAB VERSUS PHACO ONLY IN EYES WITH ADVANCED OR END-STAGE GLAUCOMA WITH CONTROLLED INTRAOCULAR PRESSURE AND VISUALLY SIGNIFICANT CATARACT Liaska.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
Sponsored by the National Eye Institute,
Comparison of efficacy and safety of Travoprost and Bimatoprost plus Timolol fixed combinations in open angle glaucoma patients previously treated with.
Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study De Moraes CG, Demirel S, Gardiner SK, et.
The Ocular Hypertension Treatment Study Group (OHTS)
Effect of East Asian Race on Selective Laser Trabeculoplasty ASCRS 2011 Minerva Kim Johns Hopkins University Lawrence F. Jindra, MD Columbia University.
Bromfenac Sodium Hydrate is Effective in Treating Intraoperative Discomfort during Selective Laser Trabeculoplasty ASCRS 2009 Marie T. Natale Floral Park.
Introduction to operative dentistry
Glaucoma Madhav Vempali Vempali Medical Ltd. Glaucoma The healthy eye Light rays enter the eye through the cornea, pupil and lens. These light rays are.
Six-Year Longevity of Selective Laser Trabeculoplasty as Primary Therapy in Patients with Glaucoma ASCRS 2009 Lawrence F. Jindra, MD Columbia University.
Effect of Previous Argon Laser Trabeculoplasty on Selective Laser Trabeculoplasty ASCRS 2011 Lawrence F. Jindra, MD Columbia University Winthrop University.
Evidence-Based Mental Health PSYC 377. Structure of the Presentation 1. Describe EBP issues 2. Categorize EBP issues 3. Assess the quality of ‘evidence’
The Diabetic Retinopathy Clinical Research Network
(Relates to Chapter 22, “Nursing Management: Visual and Auditory Problems,” in the textbook) Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier.
The Diabetic Retinopathy Clinical Research Network
PROTECTING CELLS IN THE EYE AT RISK OF DAMGE FROM GLAUCOMA
Halil Ates1, Suzan Guven Yilmaz1, Murat Erbezci2
시야검사의 이해 서울성모병원 안 명 덕.
Selective laser trabeculoplasty in Korean eyes with medically uncontrolled pseudoexfoliation glaucoma Su Chan Lee1, Jung Hyun Lee1,
Ophthalmology – Raised IOP Referrals (Adults only)
Target IOP Update Mohamed Yasser Sayed Saif Beni Suef University
Safety of medication reduction for Primary Angle Closure (PAC) –
Chapter 12 Single-Case Evaluation Designs
Effect of Selective Laser Trabeculoplasty on
From: The Effects of Study Design and Spectrum Bias on the Evaluation of Diagnostic Accuracy of Confocal Scanning Laser Ophthalmoscopy in Glaucoma Invest.
Winthrop University Hospital
Glaucoma: Detect, Diagnose, And Monitor The Silent Thief of Vision
Goals & Guidelines A summary of international guidelines for CHD
Winthrop University Hospital
Floral Park Ophthalmology Winthrop University Hospital
Presentation transcript:

Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye

Progression

Definition of progression A patient’s glaucoma is deemed to have progressed if structural and (or) functional changes, associated with the disease, are verifiably detected on clinical examination and (or) testing. The clinical significance of this progression, and the actions taken, will be influenced by: –the extent of damage prior to the change, and –the threat of visual handicap if further progression were to occur. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Methods of detecting progression Progression may be detected, clinically or with the aid of various technological investigations, as loss of tissue (structural) and/or vision (function). Careful ophthalmoscopy and precise documentation (i.e., photography or imaging) may confirm loss of RNFL or optic disc tissue over time. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Methods of detecting progression (cont’d) Confirming progressive vision loss requires threshold evaluation of the peripheral field. In both instances, the potential for greater sensitivity and quantification of change may exist for technologically based evaluations compared with clinical examinations alone. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Endpoints for conversion to, or progression of, glaucoma in major RCTs StudyEvent measuredEndpoints for event measured in both arms of study Total endpoints, % OHTSConversion to OAG ODP VFP ODP and VFP EGPSConversion to OAG ODP VFP CNTGSProgression of OAG ODP VFP EMGTSProgression of OAG ODP VFP ODP and VFP Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Progression — technology choices Recommendation Assessing disease severity is important to determine which tests might be most useful for each individual. Patients with glaucoma should be monitored with both structural and functional tests, as progression can be detected by either method alone [Level 2 1 ]. 1. Artes PH, et al. Prog Retin Eye Res 2005;24:333–54. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

VF progression endpoints for the major glaucoma RCTs RCTVF endpoint CNTGSDeepening and (or) expansion of existing scotomas and (or) new scotomas confirmed on 2 of 3, or 4 of 5 follow-up VFs AGISIncrease in VF score of 4 units on a scale of 0–20 from 2 baseline Humphrey 24-2 full-threshold VFs CIGTSIncrease in VF score of 3 units on a scale of 0–20 (slightly different from that used in AGIS) from baseline EMGTSThree adjacent points showing significant progression according to the Humphrey Glaucoma Change Probability assessment CGSFour of 8 points showed significant progression according to the Humphrey Glaucoma Change Probability assessment on 2 of 3 VFs Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Advantages and disadvantages of event-based and trend-based approaches to VF progression Type of progression analysis AdvantagesDisadvantages Event analysisEarlier detection of change Fewer tests required Intertest variability may result in change reverting to baseline No rate of change calculation possible Trend analysisRate of change (and prognosis) possible Allows clinician to tailor aggressiveness of therapy More robust in the face of intertest variability More tests and longer follow- up required Insensitive to minor changes at specific loci in the VF Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Progression — correlation between structure and function Recommendation It is recommended that a correlation between structural and functional changes be sought in suspected progression, even though it is more common for a change to be detected with one or the other independently [Level ]. 1. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:487– Kass MA, et al. Arch Ophthalmol 2002;120:701– Heijl A, et al. Arch Ophthalmol 2002;120:1268– Miglior S, et al Ophthalmology 2002;109:1612–21. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Risk factors and their relationship to VF progression examined in the landmark RCTs CharacteristicCNTGSCIGTSEMGTSAGISCGS AgeNoYes Baseline IOPNoNRYesNRNo Severity of VF damage* NoYes Yes, but opposite direction from other trials No IOP over follow-up YesNoYes Intervisit IOP fluctuation NR NoYes † No *Positively associated if more severe baseline VF damage resulted in greater degree of VF progression † Positive association in patients with low mean IOPs and not high mean IOPs Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Risk factors and their relationship to VF progression examined in the landmark RCTs CharacteristicCNTGSCIGTSEMGTSAGISCGS Disc hemorrhageYesNRYesNR MigraineYesNR No RaceNon- Asian Non-whiteNRNoNR GenderFemaleNo Male ‡ Female PseudoexfoliationNR YesNRNo DiabetesNoYesNoYesNo Anticardiolipin antibody NR Yes ‡ Positive association in ATT and not TAT sequence Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Progression significant for the patient The significance of a detectable structural and (or) functional change would be different for different patients. The ophthalmologist’s response should reflect the significance to the patient. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Progression significant for the patient (cont’d) Significance and action taken would be influenced by some of the following considerations: –What is the baseline level of glaucomatous damage (i.e., is the VF full with a nearly normal-appearing disc, or is fixation threatened in 3 of 4 quadrants)? –What is the status of the fellow eye? –What is the health of the patient and life expectancy? –What are the visual demands of the patient (e.g., is he or she still driving)? –What is the next step? Is it heightened surveillance or is it incisional surgery? –What is the patient’s interpretation of the change and the proposed actions? Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Visual field — progression confirmation Recommendation The clinician’s response to a new progressive event should be to confirm the change with a repeat test. VFs may need to be performed more frequently during periods of apparent progression. Ultimately, it is most important to calculate the rate of progression over time [Consensus]. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Number of annual VF tests needed to detect total mean deviation change over 2, 3, and 5 years Total mean deviation change, dB 2 years3 years5 years – – – Adapted from: Chauhan BC, et al. Br J Ophthalmol 2008;92:569–73. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Visual field — baseline Recommendation In order to establish a good baseline and to detect possible rapid progression, several VFs should be performed at regular intervals in the first 2 years [Consensus]. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Frequency of follow-up Frequency of follow-up is influenced by a number of factors. Patients with stable glaucoma, or ocular hypertension who are on treatment, need assessment at least once a year. Depending on disease severity, other patients will require more frequent assessments. Clinical judgment and common sense should be exercised when dealing with very elderly patients who travel long distances for follow-up, particularly during the winter. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Recommended clinical assessment * intervals for stable † chronic glaucomas StageInterval Glaucoma suspects 1  2 years Early glaucomaAt least every 12 months Moderate glaucomaAt least every 6 months Advanced glaucoma ‡ At least every 4 months * Assessments might include any of the components listed in Table 2 in addition to documentation of the optic disc and VF testing. † More frequent evaluations may be necessary if indications listed in Table 17 are noted. ‡ It may be necessary to see patients with advanced glaucoma very frequently (weeks or days) if their IOP is poorly controlled, progression appears rapid or fixation is threatened. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Indications for more frequent follow-up or heightened surveillance On the basis of the historyOn the basis of the exam Suspect adherenceSide effect to glaucoma medication Systemic drug change (new corticosteroids or antihypertensives) Intervening eye infection (especially for postoperative eyes), trauma, surgery or iritis Change in health statusIOP above target Change in health insurance (i.e., access to medications) Disc change Change in social history (i.e., availability of caregivers) VF change Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.

Progression: Treatment goals Some degree of progression may be unavoidable in glaucoma. Goals for the clinician include: –measuring and minimizing the progression, –preserving or enhancing QOL, and –choosing a management scheme that is appropriate and acceptable to the patient. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009;44(Suppl 1):S1  S93.